Outset Medical, Inc. (NASDAQ:OM) Given Consensus Rating of “Hold” by Brokerages

Shares of Outset Medical, Inc. (NASDAQ:OM) have received a consensus rating of “Hold” from the five research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $10.00.

A number of brokerages recently issued reports on OM. Wall Street Zen lowered Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. BTIG Research reduced their target price on Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. TD Cowen restated a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a research note on Friday, March 27th.

Outset Medical Stock Performance

Shares of OM opened at $4.89 on Friday. Outset Medical has a 12 month low of $3.00 and a 12 month high of $21.98. The stock has a fifty day moving average price of $4.13 and a 200-day moving average price of $4.24. The company has a current ratio of 6.29, a quick ratio of 4.97 and a debt-to-equity ratio of 0.87. The firm has a market cap of $90.66 million, a PE ratio of -1.18 and a beta of 1.92.

Outset Medical (NASDAQ:OM) last issued its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.04). The firm had revenue of $27.86 million during the quarter, compared to analysts’ expectations of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. Equities research analysts predict that Outset Medical will post -3.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Outset Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BML Capital Management LLC purchased a new position in Outset Medical in the 4th quarter worth $2,015,000. Los Angeles Capital Management LLC purchased a new position in Outset Medical in the 4th quarter worth $29,000. Bank of New York Mellon Corp grew its position in Outset Medical by 4.1% during the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock worth $239,000 after purchasing an additional 2,435 shares during the period. Sei Investments Co. grew its position in Outset Medical by 15.5% during the 1st quarter. Sei Investments Co. now owns 35,366 shares of the company’s stock worth $136,000 after purchasing an additional 4,738 shares during the period. Finally, Renaissance Technologies LLC grew its position in Outset Medical by 391.3% during the 1st quarter. Renaissance Technologies LLC now owns 222,075 shares of the company’s stock worth $853,000 after purchasing an additional 176,870 shares during the period.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.